HOLX · Insider Trading
Hologic Inc
Every open-market purchase and sale reported by HOLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | Nanaz Mohtashami | Director | A | +3,190 | — |
| 2026-03-02 | Ludwig Hantson | Director | A | +3,190 | — |
| 2026-03-02 | Amy McBride Wendell | Director | A | +3,190 | — |
| 2026-03-02 | Martin D Madaus | Director | A | +3,190 | — |
| 2026-03-02 | Stacey D. Stewart | Director | A | +3,190 | — |
| 2026-03-02 | Wayde D. McMillan | Director | A | +3,190 | — |
| 2026-03-02 | Charles J Dockendorff | Director | A | +3,190 | — |
| 2026-03-02 | Anne M. Liddy | General Counsel | F | −185 | −$13.94K |
| 2026-03-02 | Christiana Stamoulis | Director | A | +3,190 | — |
| 2026-02-12 | Mark W. Horvath | President, Breast & Skeletal | F | −113 | −$8.49K |
| 2026-02-03 | Diana De Walt | SVP, Human Resources | F | −4,416 | −$330.89K |
| 2026-02-03 | Diana De Walt | SVP, Human Resources | F | −4,416 | −$330.89K |
| 2025-12-16 | Brandon Schnittker | President, GYN Surgical | F | −90 | −$6.75K |
| 2025-11-18 | Karleen Marie Oberton | Chief Financial Officer | F | −1,333 | −$98.84K |
| 2025-11-18 | Jennifer M Schneiders | President, Diag. Solutions | F | −561 | −$41.60K |
| 2025-11-18 | Benjamin Jordan Cohn | Principal Accounting Officer | F | −187 | −$13.87K |
| 2025-11-18 | Anne M. Liddy | General Counsel | F | −337 | −$24.99K |
| 2025-11-18 | Jan Verstreken | Group President, International | F | −196 | −$14.53K |
| 2025-11-18 | Essex D Mitchell | Chief Operating Officer | F | −1,342 | −$99.51K |
| 2025-11-18 | Brandon Schnittker | President, GYN Surgical | F | −178 | −$13.20K |
| 2025-11-18 | Stephen P Macmillan | Chairman, President and CEO | F | −6,874 | −$509.71K |
| 2025-11-12 | Mark W. Horvath | President, Breast & Skeletal | A | +13,458 | — |
| 2025-11-12 | Benjamin Jordan Cohn | Principal Accounting Officer | MIXED | +3,788 | −$93.38K |
| 2025-11-12 | Jan Verstreken | Group President, International | MIXED | +15,225 | −$118.50K |
| 2025-11-12 | Essex D Mitchell | Chief Operating Officer | MIXED | +41,478 | −$417.89K |
| 2025-11-12 | Jennifer M Schneiders | President, Diag. Solutions | MIXED | +29,422 | −$64.08K |
| 2025-11-12 | Anne M. Liddy | General Counsel | MIXED | +16,802 | −$51.63K |
| 2025-11-12 | Karleen Marie Oberton | Chief Financial Officer | MIXED | +32,865 | −$806.64K |
| 2025-11-12 | Stephen P Macmillan | Chairman, President and CEO | MIXED | +112,498 | −$4.23M |
| 2025-11-12 | Brandon Schnittker | President, GYN Surgical | MIXED | +11,686 | −$31.79K |
| 2025-11-06 | Benjamin Jordan Cohn | Principal Accounting Officer | A | +2,656 | — |
| 2025-11-06 | Jan Verstreken | Group President, International | A | +15,196 | — |
| 2025-11-06 | Mark W. Horvath | President, Breast & Skeletal | A | +2,278 | — |
| 2025-11-06 | Karleen Marie Oberton | Chief Financial Officer | A | +17,095 | — |
| 2025-11-06 | Essex D Mitchell | Chief Operating Officer | A | +9,116 | — |
| 2025-11-06 | Stephen P Macmillan | Chairman, President and CEO | A | +83,589 | — |
| 2025-10-22 | Christiana Stamoulis | Director | MIXED | — | −$274.10K |
| 2025-09-23 | Stephen P Macmillan | Chairman, President and CEO | MIXED | — | −$3.74M |
| 2025-06-03 | Brandon Schnittker | Div. President, GYN Surgical | F | −69 | −$4.29K |
| 2025-05-09 | Martin D Madaus | Director | Buy | +5,445 | +$300.76K |
| 2025-04-09 | Wayde D. McMillan | Director | A | +1,742 | — |
| 2025-02-28 | Christiana Stamoulis | Director | A | +1,864 | — |
| 2025-02-28 | Stacey D. Stewart | Director | A | +1,864 | — |
| 2025-02-28 | Amy McBride Wendell | Director | A | +1,864 | — |
| 2025-02-28 | Martin D Madaus | Director | A | +1,864 | — |
| 2025-02-28 | Ludwig Hantson | Director | A | +1,864 | — |
| 2025-02-28 | Nanaz Mohtashami | Director | A | +1,864 | — |
| 2025-02-28 | Charles J Dockendorff | Director | A | +1,864 | — |
| 2025-02-12 | Mark W. Horvath | Div. Pres., Breast & Skeletal | A | +958 | — |
| 2024-12-17 | Brandon Schnittker | Div. President, GYN Surgical | F | −90 | −$6.63K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Stephen P Macmillan | Chairman, President and CEO | 2,570,666 | $195.40M |
| John M. Griffin | General Counsel | 182,514 | $13.87M |
| Karleen Marie Oberton | Chief Financial Officer | 150,735 | $11.46M |
| Jan Verstreken | Group President, International | 134,039 | $10.19M |
| Essex D Mitchell | Chief Operating Officer | 77,610 | $5.90M |
| Christiana Stamoulis | Director | 50,526 | $3.84M |
| Jennifer M Schneiders | President, Diag. Solutions | 41,318 | $3.14M |
| Anne M. Liddy | General Counsel | 28,052 | $2.13M |
| Amy McBride Wendell | Director | 25,784 | $1.96M |
| Erik S Anderson | Div. Pres., Breast & Skeletal | 23,231 | $1.77M |
| Mark W. Horvath | President, Breast & Skeletal | 23,026 | $1.75M |
| Charles J Dockendorff | Director | 21,996 | $1.67M |
| Benjamin Jordan Cohn | Principal Accounting Officer | 17,884 | $1.36M |
| Brandon Schnittker | President, GYN Surgical | 17,512 | $1.33M |
| Ludwig Hantson | Director | 16,146 | $1.23M |
| Martin D Madaus | Director | 10,841 | $824.02K |
| Stacey D. Stewart | Director | 8,358 | $635.29K |
| Diana De Walt | SVP, Human Resources | 7,603 | $577.90K |
| Nanaz Mohtashami | Director | 7,371 | $560.27K |
| Wayde D. McMillan | Director | 4,932 | $374.88K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HOLX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.